Mission Bio

Today, we're thrilled to announce the Tapestri Single-cell Multiple Myeloma Multiomics Solution! 🎉 This groundbreaking product suite is set to transform MM research and therapeutic development, offering unparalleled insights into disease evolution and biology at the single-cell level. 🔬 Our new solution integrates genomic, proteomic, and clonotypic assessments in a single assay, providing comprehensive clonal and subclonal insights that surpass existing bulk methodologies. This will empower researchers and drug developers to fully dissect the molecular and cellular landscape of myeloid progression, understand therapy resistance, and address disease relapse more effectively. Stay tuned for more details, including late-breaking data to be presented at the European Hematology Association (EHA) Congress on June 14. 📅 Check out our press release to learn more https://bit.ly/4e9AEtE #multiplemyeloma #singlecell #multiomics #pressrelease #eha2024

🚨 Last chance to register 🚨 In the next installment in our live webinar series, hear from Morgan Drucker, MD, Pediatric Hematology/Oncology Fellow at Cincinnati Children's Hospital, where she will present findings from datasets generated by her team using single-cell multi-omics. She will discuss two distinct patient cohorts: adults with NPM1-mutated AML and pediatric patients with KMT2A-rearranged acute leukemias, whose underlying genetic changes (NPM1 mutations and KMT2A rearrangements) both rely on interactions between the protein menin and KMT2A. 📅 Thursday, February 27 ⏰ 11:30a ET | 8:30a PT Register here ➡️ https://lnkd.in/gs-DH7fZ

We’re excited to be at AACR IO 2025 in Los Angeles, where the latest in cancer immunotherapy and cellular therapy research & development will take center stage. At Mission Bio, we’re empowering researchers and drug developers with single-cell multiomics to uncover deeper insights into therapy response, resistance, and cell therapy characterization—helping to ensure safer, more effective treatments. Come say hello at Booth #112 to learn more. https://lnkd.in/dX-ttJbU

Attending hubXchange Advanced Therapies Xchange next week? Be sure to catch George Dorfman's presentation - he'll be sharing how Mission Bio has developed precise, fast single-cell assays to characterize CGT assets for regulatory QC testing, as well as clinical monitoring of on-treatment patients. You can learn more about utilizing Tapestri for characterization of CAR T cell products here ➡️ https://lnkd.in/gy4TMJdF

If you're attending #Tandem25, be sure to catch Nils Wellhausen on Thursday, February 13 - he'll be presenting "Selection for an HIV-Resistant Immune System By Multiplex Epitope Base-Edited CD45 CAR-T Cell Therapy." Didn't make it to #Tandem25 this year? You can hear about Dr. Wellhausen's exciting research in our latest on-demand webinar here ➡️ https://lnkd.in/gge7Zvvi

🚨 Webinar Alert! 🚨 In the next installment in our live webinar series, hear from Morgan Drucker, MD, Pediatric Hematology/Oncology Fellow at Cincinnati Children's Hospital Medical Center, where she will present findings from datasets generated by her team using single-cell multi-omics. She will discuss two distinct patient cohorts: adults with NPM1-mutated AML and pediatric patients with KMT2A-rearranged acute leukemias, whose underlying genetic changes (NPM1 mutations and KMT2A rearrangements) both rely on interactions between the protein menin and KMT2A. 📅 Thursday, February 27 ⏰ 11:30a ET | 8:30a PT Register today to save your spot! ➡️ https://lnkd.in/gj9cANGV

⏰ One week away! ⏰ Join us for a live webinar Thursday, January 30th where Dr. Nils Wellhausen, University of Pennsylvania School of Medicine, will share groundbreaking insights into the potential of epitope editing to revolutionize immunotherapies for blood cancers and HIV reservoir elimination. In this webinar, Dr. Wellhausen will cover: 🎯 Targeted Immunotherapy: How epitope editing enables safe, CD45-directed CAR-T therapies for blood cancers. ❌ HIV Reservoir Eradication: The development of dual-edited CART45 cells to eliminate HIV-infected cells while resisting infection. 🔬 Broad Applicability: Exploring the versatility of the CD45 platform across multiple therapeutic modalities, including BTEs. 💡 Advanced Editing Insights: Using the Tapestri platform to analyze editing outcomes, revealing high co-occurrence of precise edits with minimal off-target effects. Register here ➡️ https://lnkd.in/geG2K7Dd

📅 Save the date! Join us for a live webinar Thursday, January 30th  where Dr. Nils Wellhausen, University of Pennsylvania School of Medicine, will share groundbreaking insights into the potential of epitope editing to revolutionize immunotherapies for blood cancers and HIV reservoir elimination. In this webinar, Dr. Wellhausen will cover: 🎯 Targeted Immunotherapy: How epitope editing enables safe, CD45-directed CAR-T therapies for blood cancers. ❌ HIV Reservoir Eradication: The development of dual-edited CART45 cells to eliminate HIV-infected cells while resisting infection. 🔬 Broad Applicability: Exploring the versatility of the CD45 platform across multiple therapeutic modalities, including BTEs. 💡 Advanced Editing Insights: Using the Tapestri platform to analyze editing outcomes, revealing high co-occurrence of precise edits with minimal off-target effects. Register today to save your spot! https://lnkd.in/gutpjBMe

Last chance to register! Join us this week for a lunch-and-learn seminar at University of Alabama at Birmingham with our own Shawn Clouthier and Erik Marchese MS, MBA. They'll be covering: 🧬 An overview of the Tapestri single-cell DNA+protein multiomics platform. 💡 Recent single-cell innovations, including sample multiplexing and novel assays for Multiple Myeloma, Myeloid Diseases, Genome Integrity, and Gene Editing characterization. 📈 Tracking cancer clonal evolution and characterizing CRISPR-edited disease models or cell therapies using single-cell multiomics. Register now to save your spot! ➡️ https://lnkd.in/gtMiRRSz

🇮🇹 🔬 The 2024 ESGCT conference in Rome, Italy showcased the latest innovations in gene and cell therapy, with a focus on developments in CAR T- cell therapies, gene-editing tools, and immunotherapy strategies. We took a moment to take a look back at some of the key themes and exciting advancements presented by the expert attendees! Read it here 👉 https://lnkd.in/gmm5rg6E